nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00218	0.00218	CcSEcCtD
Oritavancin—Nausea—Tolazamide—type 2 diabetes mellitus	0.00218	0.00218	CcSEcCtD
Oritavancin—Eosinophilia—Losartan—type 2 diabetes mellitus	0.00218	0.00218	CcSEcCtD
Oritavancin—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00217	0.00217	CcSEcCtD
Oritavancin—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00216	0.00216	CcSEcCtD
Oritavancin—Rash—Nateglinide—type 2 diabetes mellitus	0.00214	0.00214	CcSEcCtD
Oritavancin—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.00214	0.00214	CcSEcCtD
Oritavancin—Connective tissue disorder—Valsartan—type 2 diabetes mellitus	0.00214	0.00214	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Pioglitazone—type 2 diabetes mellitus	0.00212	0.00212	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.00212	0.00212	CcSEcCtD
Oritavancin—Anaemia—Glyburide—type 2 diabetes mellitus	0.00212	0.00212	CcSEcCtD
Oritavancin—Oedema peripheral—Orlistat—type 2 diabetes mellitus	0.00212	0.00212	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.0021	0.0021	CcSEcCtD
Oritavancin—Angioedema—Glyburide—type 2 diabetes mellitus	0.0021	0.0021	CcSEcCtD
Oritavancin—Nausea—Acarbose—type 2 diabetes mellitus	0.00209	0.00209	CcSEcCtD
Oritavancin—Pruritus—Repaglinide—type 2 diabetes mellitus	0.00208	0.00208	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Sitagliptin—type 2 diabetes mellitus	0.00206	0.00206	CcSEcCtD
Oritavancin—Malnutrition—Gliclazide—type 2 diabetes mellitus	0.00206	0.00206	CcSEcCtD
Oritavancin—Infection—Bromocriptine—type 2 diabetes mellitus	0.00204	0.00204	CcSEcCtD
Oritavancin—Nausea—Nateglinide—type 2 diabetes mellitus	0.00202	0.00202	CcSEcCtD
Oritavancin—Cardiac disorder—Valsartan—type 2 diabetes mellitus	0.00202	0.00202	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.00201	0.00201	CcSEcCtD
Oritavancin—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.00201	0.00201	CcSEcCtD
Oritavancin—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.00201	0.00201	CcSEcCtD
Oritavancin—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.002	0.002	CcSEcCtD
Oritavancin—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.00199	0.00199	CcSEcCtD
Oritavancin—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.00197	0.00197	CcSEcCtD
Oritavancin—Immune system disorder—Valsartan—type 2 diabetes mellitus	0.00197	0.00197	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.00196	0.00196	CcSEcCtD
Oritavancin—Mediastinal disorder—Valsartan—type 2 diabetes mellitus	0.00196	0.00196	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.00196	0.00196	CcSEcCtD
Oritavancin—Myalgia—Glyburide—type 2 diabetes mellitus	0.00195	0.00195	CcSEcCtD
Oritavancin—Oedema peripheral—Metformin—type 2 diabetes mellitus	0.00195	0.00195	CcSEcCtD
Oritavancin—Connective tissue disorder—Metformin—type 2 diabetes mellitus	0.00195	0.00195	CcSEcCtD
Oritavancin—Immune system disorder—Orlistat—type 2 diabetes mellitus	0.00194	0.00194	CcSEcCtD
Oritavancin—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	0.00194	0.00194	CcSEcCtD
Oritavancin—Urticaria—Glipizide—type 2 diabetes mellitus	0.00193	0.00193	CcSEcCtD
Oritavancin—Anaemia—Gliclazide—type 2 diabetes mellitus	0.00191	0.00191	CcSEcCtD
Oritavancin—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.0019	0.0019	CcSEcCtD
Oritavancin—Malnutrition—Valsartan—type 2 diabetes mellitus	0.00189	0.00189	CcSEcCtD
Oritavancin—Angioedema—Gliclazide—type 2 diabetes mellitus	0.00188	0.00188	CcSEcCtD
Oritavancin—Malnutrition—Orlistat—type 2 diabetes mellitus	0.00187	0.00187	CcSEcCtD
Oritavancin—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00187	0.00187	CcSEcCtD
Oritavancin—Eosinophilia—Ramipril—type 2 diabetes mellitus	0.00187	0.00187	CcSEcCtD
Oritavancin—Rash—Repaglinide—type 2 diabetes mellitus	0.00186	0.00186	CcSEcCtD
Oritavancin—Bronchospasm—Ramipril—type 2 diabetes mellitus	0.00185	0.00185	CcSEcCtD
Oritavancin—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.00185	0.00185	CcSEcCtD
Oritavancin—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.00185	0.00185	CcSEcCtD
Oritavancin—Headache—Repaglinide—type 2 diabetes mellitus	0.00184	0.00184	CcSEcCtD
Oritavancin—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	0.00184	0.00184	CcSEcCtD
Oritavancin—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00184	0.00184	CcSEcCtD
Oritavancin—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.00184	0.00184	CcSEcCtD
Oritavancin—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.00184	0.00184	CcSEcCtD
Oritavancin—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	0.00184	0.00184	CcSEcCtD
Oritavancin—Urticaria—Glimepiride—type 2 diabetes mellitus	0.0018	0.0018	CcSEcCtD
Oritavancin—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.0018	0.0018	CcSEcCtD
Oritavancin—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00179	0.00179	CcSEcCtD
Oritavancin—Immune system disorder—Metformin—type 2 diabetes mellitus	0.00179	0.00179	CcSEcCtD
Oritavancin—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.00179	0.00179	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.00177	0.00177	CcSEcCtD
Oritavancin—Myalgia—Gliclazide—type 2 diabetes mellitus	0.00176	0.00176	CcSEcCtD
Oritavancin—Rash—Rosiglitazone—type 2 diabetes mellitus	0.00175	0.00175	CcSEcCtD
Oritavancin—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00175	0.00175	CcSEcCtD
Oritavancin—Nausea—Repaglinide—type 2 diabetes mellitus	0.00175	0.00175	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.00174	0.00174	CcSEcCtD
Oritavancin—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00174	0.00174	CcSEcCtD
Oritavancin—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.00174	0.00174	CcSEcCtD
Oritavancin—Angioedema—Valsartan—type 2 diabetes mellitus	0.00173	0.00173	CcSEcCtD
Oritavancin—Malnutrition—Metformin—type 2 diabetes mellitus	0.00172	0.00172	CcSEcCtD
Oritavancin—Pruritus—Glipizide—type 2 diabetes mellitus	0.00172	0.00172	CcSEcCtD
Oritavancin—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00172	0.00172	CcSEcCtD
Oritavancin—Angioedema—Orlistat—type 2 diabetes mellitus	0.00171	0.00171	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.00171	0.00171	CcSEcCtD
Oritavancin—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.00169	0.00169	CcSEcCtD
Oritavancin—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.00169	0.00169	CcSEcCtD
Oritavancin—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00167	0.00167	CcSEcCtD
Oritavancin—Infection—Gliclazide—type 2 diabetes mellitus	0.00167	0.00167	CcSEcCtD
Oritavancin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00167	0.00167	CcSEcCtD
Oritavancin—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.00167	0.00167	CcSEcCtD
Oritavancin—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.00166	0.00166	CcSEcCtD
Oritavancin—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00165	0.00165	CcSEcCtD
Oritavancin—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00165	0.00165	CcSEcCtD
Oritavancin—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00164	0.00164	CcSEcCtD
Oritavancin—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00163	0.00163	CcSEcCtD
Oritavancin—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00163	0.00163	CcSEcCtD
Oritavancin—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.00163	0.00163	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.00162	0.00162	CcSEcCtD
Oritavancin—Myalgia—Valsartan—type 2 diabetes mellitus	0.00161	0.00161	CcSEcCtD
Oritavancin—Dizziness—Glipizide—type 2 diabetes mellitus	0.00161	0.00161	CcSEcCtD
Oritavancin—Pruritus—Glimepiride—type 2 diabetes mellitus	0.00161	0.00161	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.0016	0.0016	CcSEcCtD
Oritavancin—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.0016	0.0016	CcSEcCtD
Oritavancin—Myalgia—Orlistat—type 2 diabetes mellitus	0.00159	0.00159	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.00158	0.00158	CcSEcCtD
Oritavancin—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00155	0.00155	CcSEcCtD
Oritavancin—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00155	0.00155	CcSEcCtD
Oritavancin—Vomiting—Glipizide—type 2 diabetes mellitus	0.00155	0.00155	CcSEcCtD
Oritavancin—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00154	0.00154	CcSEcCtD
Oritavancin—Infection—Valsartan—type 2 diabetes mellitus	0.00154	0.00154	CcSEcCtD
Oritavancin—Rash—Glipizide—type 2 diabetes mellitus	0.00154	0.00154	CcSEcCtD
Oritavancin—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00153	0.00153	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.00153	0.00153	CcSEcCtD
Oritavancin—Headache—Glipizide—type 2 diabetes mellitus	0.00153	0.00153	CcSEcCtD
Oritavancin—Infection—Orlistat—type 2 diabetes mellitus	0.00152	0.00152	CcSEcCtD
Oritavancin—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00152	0.00152	CcSEcCtD
Oritavancin—Anaemia—Irbesartan—type 2 diabetes mellitus	0.0015	0.0015	CcSEcCtD
Oritavancin—Dizziness—Glimepiride—type 2 diabetes mellitus	0.0015	0.0015	CcSEcCtD
Oritavancin—Skin disorder—Valsartan—type 2 diabetes mellitus	0.0015	0.0015	CcSEcCtD
Oritavancin—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.0015	0.0015	CcSEcCtD
Oritavancin—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.0015	0.0015	CcSEcCtD
Oritavancin—Urticaria—Glyburide—type 2 diabetes mellitus	0.00149	0.00149	CcSEcCtD
Oritavancin—Angioedema—Irbesartan—type 2 diabetes mellitus	0.00149	0.00149	CcSEcCtD
Oritavancin—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.00149	0.00149	CcSEcCtD
Oritavancin—Skin disorder—Orlistat—type 2 diabetes mellitus	0.00148	0.00148	CcSEcCtD
Oritavancin—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.00148	0.00148	CcSEcCtD
Oritavancin—Myalgia—Metformin—type 2 diabetes mellitus	0.00147	0.00147	CcSEcCtD
Oritavancin—Headache—Pioglitazone—type 2 diabetes mellitus	0.00146	0.00146	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.00146	0.00146	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00145	0.00145	CcSEcCtD
Oritavancin—Nausea—Glipizide—type 2 diabetes mellitus	0.00145	0.00145	CcSEcCtD
Oritavancin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00144	0.00144	CcSEcCtD
Oritavancin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00144	0.00144	CcSEcCtD
Oritavancin—Rash—Glimepiride—type 2 diabetes mellitus	0.00143	0.00143	CcSEcCtD
Oritavancin—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00143	0.00143	CcSEcCtD
Oritavancin—Rash—Sitagliptin—type 2 diabetes mellitus	0.00143	0.00143	CcSEcCtD
Oritavancin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.00143	0.00143	CcSEcCtD
Oritavancin—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.00143	0.00143	CcSEcCtD
Oritavancin—Headache—Glimepiride—type 2 diabetes mellitus	0.00142	0.00142	CcSEcCtD
Oritavancin—Headache—Sitagliptin—type 2 diabetes mellitus	0.00142	0.00142	CcSEcCtD
Oritavancin—Anaemia—Losartan—type 2 diabetes mellitus	0.00142	0.00142	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.00141	0.00141	CcSEcCtD
Oritavancin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.0014	0.0014	CcSEcCtD
Oritavancin—Angioedema—Losartan—type 2 diabetes mellitus	0.0014	0.0014	CcSEcCtD
Oritavancin—Infection—Metformin—type 2 diabetes mellitus	0.0014	0.0014	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.00139	0.00139	CcSEcCtD
Oritavancin—Myalgia—Irbesartan—type 2 diabetes mellitus	0.00139	0.00139	CcSEcCtD
Oritavancin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00138	0.00138	CcSEcCtD
Oritavancin—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.00138	0.00138	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.00138	0.00138	CcSEcCtD
Oritavancin—Skin disorder—Metformin—type 2 diabetes mellitus	0.00137	0.00137	CcSEcCtD
Oritavancin—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00136	0.00136	CcSEcCtD
Oritavancin—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.00136	0.00136	CcSEcCtD
Oritavancin—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00136	0.00136	CcSEcCtD
Oritavancin—Nausea—Glimepiride—type 2 diabetes mellitus	0.00135	0.00135	CcSEcCtD
Oritavancin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00135	0.00135	CcSEcCtD
Oritavancin—Urticaria—Gliclazide—type 2 diabetes mellitus	0.00134	0.00134	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00133	0.00133	CcSEcCtD
Oritavancin—Pruritus—Glyburide—type 2 diabetes mellitus	0.00133	0.00133	CcSEcCtD
Oritavancin—Infection—Irbesartan—type 2 diabetes mellitus	0.00132	0.00132	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.00132	0.00132	CcSEcCtD
Oritavancin—Malnutrition—Ramipril—type 2 diabetes mellitus	0.00131	0.00131	CcSEcCtD
Oritavancin—Myalgia—Losartan—type 2 diabetes mellitus	0.0013	0.0013	CcSEcCtD
Oritavancin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.0013	0.0013	CcSEcCtD
Oritavancin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.0013	0.0013	CcSEcCtD
Oritavancin—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.0013	0.0013	CcSEcCtD
Oritavancin—Rash—Bromocriptine—type 2 diabetes mellitus	0.00129	0.00129	CcSEcCtD
Oritavancin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.00129	0.00129	CcSEcCtD
Oritavancin—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00129	0.00129	CcSEcCtD
Oritavancin—Headache—Bromocriptine—type 2 diabetes mellitus	0.00128	0.00128	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.00128	0.00128	CcSEcCtD
Oritavancin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00128	0.00128	CcSEcCtD
Oritavancin—Infection—Losartan—type 2 diabetes mellitus	0.00124	0.00124	CcSEcCtD
Oritavancin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00124	0.00124	CcSEcCtD
Oritavancin—Urticaria—Valsartan—type 2 diabetes mellitus	0.00123	0.00123	CcSEcCtD
Oritavancin—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00123	0.00123	CcSEcCtD
Oritavancin—Tachycardia—Losartan—type 2 diabetes mellitus	0.00122	0.00122	CcSEcCtD
Oritavancin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00122	0.00122	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.00122	0.00122	CcSEcCtD
Oritavancin—Urticaria—Orlistat—type 2 diabetes mellitus	0.00121	0.00121	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.00121	0.00121	CcSEcCtD
Oritavancin—Angioedema—Ramipril—type 2 diabetes mellitus	0.0012	0.0012	CcSEcCtD
Oritavancin—Vomiting—Glyburide—type 2 diabetes mellitus	0.00119	0.00119	CcSEcCtD
Oritavancin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.00119	0.00119	CcSEcCtD
Oritavancin—Rash—Glyburide—type 2 diabetes mellitus	0.00118	0.00118	CcSEcCtD
Oritavancin—Dermatitis—Glyburide—type 2 diabetes mellitus	0.00118	0.00118	CcSEcCtD
Oritavancin—Headache—Glyburide—type 2 diabetes mellitus	0.00117	0.00117	CcSEcCtD
Oritavancin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.00115	0.00115	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.00115	0.00115	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.00114	0.00114	CcSEcCtD
Oritavancin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00114	0.00114	CcSEcCtD
Oritavancin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.00113	0.00113	CcSEcCtD
Oritavancin—Urticaria—Metformin—type 2 diabetes mellitus	0.00112	0.00112	CcSEcCtD
Oritavancin—Myalgia—Ramipril—type 2 diabetes mellitus	0.00112	0.00112	CcSEcCtD
Oritavancin—Nausea—Glyburide—type 2 diabetes mellitus	0.00111	0.00111	CcSEcCtD
Oritavancin—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00111	0.00111	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.00111	0.00111	CcSEcCtD
Oritavancin—Pruritus—Valsartan—type 2 diabetes mellitus	0.00109	0.00109	CcSEcCtD
Oritavancin—Pruritus—Orlistat—type 2 diabetes mellitus	0.00108	0.00108	CcSEcCtD
Oritavancin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00107	0.00107	CcSEcCtD
Oritavancin—Rash—Gliclazide—type 2 diabetes mellitus	0.00106	0.00106	CcSEcCtD
Oritavancin—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.00106	0.00106	CcSEcCtD
Oritavancin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00106	0.00106	CcSEcCtD
Oritavancin—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00106	0.00106	CcSEcCtD
Oritavancin—Headache—Gliclazide—type 2 diabetes mellitus	0.00105	0.00105	CcSEcCtD
Oritavancin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.00105	0.00105	CcSEcCtD
Oritavancin—Tachycardia—Ramipril—type 2 diabetes mellitus	0.00105	0.00105	CcSEcCtD
Oritavancin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.00105	0.00105	CcSEcCtD
Oritavancin—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00104	0.00104	CcSEcCtD
Oritavancin—Dizziness—Valsartan—type 2 diabetes mellitus	0.00102	0.00102	CcSEcCtD
Oritavancin—Dizziness—Orlistat—type 2 diabetes mellitus	0.00101	0.00101	CcSEcCtD
Oritavancin—Nausea—Gliclazide—type 2 diabetes mellitus	0.000999	0.000999	CcSEcCtD
Oritavancin—Pruritus—Metformin—type 2 diabetes mellitus	0.000996	0.000996	CcSEcCtD
Oritavancin—Urticaria—Losartan—type 2 diabetes mellitus	0.000993	0.000993	CcSEcCtD
Oritavancin—Vomiting—Valsartan—type 2 diabetes mellitus	0.000983	0.000983	CcSEcCtD
Oritavancin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000979	0.000979	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000977	0.000977	CcSEcCtD
Oritavancin—Rash—Valsartan—type 2 diabetes mellitus	0.000975	0.000975	CcSEcCtD
Oritavancin—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000974	0.000974	CcSEcCtD
Oritavancin—Vomiting—Orlistat—type 2 diabetes mellitus	0.000971	0.000971	CcSEcCtD
Oritavancin—Headache—Valsartan—type 2 diabetes mellitus	0.000968	0.000968	CcSEcCtD
Oritavancin—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000963	0.000963	CcSEcCtD
Oritavancin—Rash—Orlistat—type 2 diabetes mellitus	0.000963	0.000963	CcSEcCtD
Oritavancin—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000962	0.000962	CcSEcCtD
Oritavancin—Headache—Orlistat—type 2 diabetes mellitus	0.000957	0.000957	CcSEcCtD
Oritavancin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.00094	0.00094	CcSEcCtD
Oritavancin—Dizziness—Metformin—type 2 diabetes mellitus	0.000931	0.000931	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000925	0.000925	CcSEcCtD
Oritavancin—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000921	0.000921	CcSEcCtD
Oritavancin—Nausea—Valsartan—type 2 diabetes mellitus	0.000918	0.000918	CcSEcCtD
Oritavancin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000909	0.000909	CcSEcCtD
Oritavancin—Nausea—Orlistat—type 2 diabetes mellitus	0.000907	0.000907	CcSEcCtD
Oritavancin—Vomiting—Metformin—type 2 diabetes mellitus	0.000895	0.000895	CcSEcCtD
Oritavancin—Rash—Metformin—type 2 diabetes mellitus	0.000888	0.000888	CcSEcCtD
Oritavancin—Dermatitis—Metformin—type 2 diabetes mellitus	0.000887	0.000887	CcSEcCtD
Oritavancin—Pruritus—Losartan—type 2 diabetes mellitus	0.000884	0.000884	CcSEcCtD
Oritavancin—Headache—Metformin—type 2 diabetes mellitus	0.000882	0.000882	CcSEcCtD
Oritavancin—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000878	0.000878	CcSEcCtD
Oritavancin—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000855	0.000855	CcSEcCtD
Oritavancin—Urticaria—Ramipril—type 2 diabetes mellitus	0.000852	0.000852	CcSEcCtD
Oritavancin—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000845	0.000845	CcSEcCtD
Oritavancin—Rash—Irbesartan—type 2 diabetes mellitus	0.000838	0.000838	CcSEcCtD
Oritavancin—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000837	0.000837	CcSEcCtD
Oritavancin—Nausea—Metformin—type 2 diabetes mellitus	0.000836	0.000836	CcSEcCtD
Oritavancin—Headache—Irbesartan—type 2 diabetes mellitus	0.000832	0.000832	CcSEcCtD
Oritavancin—Dizziness—Losartan—type 2 diabetes mellitus	0.000827	0.000827	CcSEcCtD
Oritavancin—Vomiting—Losartan—type 2 diabetes mellitus	0.000795	0.000795	CcSEcCtD
Oritavancin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.00079	0.00079	CcSEcCtD
Oritavancin—Nausea—Irbesartan—type 2 diabetes mellitus	0.000789	0.000789	CcSEcCtD
Oritavancin—Rash—Losartan—type 2 diabetes mellitus	0.000788	0.000788	CcSEcCtD
Oritavancin—Dermatitis—Losartan—type 2 diabetes mellitus	0.000788	0.000788	CcSEcCtD
Oritavancin—Headache—Losartan—type 2 diabetes mellitus	0.000783	0.000783	CcSEcCtD
Oritavancin—Pruritus—Ramipril—type 2 diabetes mellitus	0.000758	0.000758	CcSEcCtD
Oritavancin—Nausea—Losartan—type 2 diabetes mellitus	0.000743	0.000743	CcSEcCtD
Oritavancin—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000733	0.000733	CcSEcCtD
Oritavancin—Dizziness—Ramipril—type 2 diabetes mellitus	0.000709	0.000709	CcSEcCtD
Oritavancin—Vomiting—Ramipril—type 2 diabetes mellitus	0.000682	0.000682	CcSEcCtD
Oritavancin—Rash—Ramipril—type 2 diabetes mellitus	0.000676	0.000676	CcSEcCtD
Oritavancin—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000675	0.000675	CcSEcCtD
Oritavancin—Headache—Ramipril—type 2 diabetes mellitus	0.000672	0.000672	CcSEcCtD
Oritavancin—Nausea—Ramipril—type 2 diabetes mellitus	0.000637	0.000637	CcSEcCtD
